{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:12:11Z","timestamp":1769429531693,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10072-020-04434-1","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T21:16:17Z","timestamp":1588194977000},"page":"2939-2945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Experience with rituximab therapy in a real-life sample of multiple sclerosis patients"],"prefix":"10.1007","volume":"41","author":[{"given":"Angelo","family":"Bellinvia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio","family":"Prestipino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Portaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Razzolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Fonderico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Fratangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Tudisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Past\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria P.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"4434_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"key":"4434_CR2","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","volume":"74","author":"RT Naismith","year":"2010","unstructured":"Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 74:1860\u20131867. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e24373","journal-title":"Neurology."},{"key":"4434_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PAJ, Arnlod D et al (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395\u2013400. https:\/\/doi.org\/10.1002\/ana.21363","journal-title":"Ann Neurol"},{"key":"4434_CR4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","volume":"265","author":"C Alcal\u00e1","year":"2018","unstructured":"Alcal\u00e1 C, Gasc\u00f3n F, P\u00e9rez-Miralles F, Gil-Perot\u00edn S, Navarr\u00e9 A, Bosc\u00e1 I, Coret F, Casanova B (2018) Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol 265:1690\u20131697. https:\/\/doi.org\/10.1007\/s00415-018-8899-3","journal-title":"J Neurol"},{"key":"4434_CR5","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bj\u00f6rck A, Fink K, Islam-Jakobsson P, Malmestr\u00f6m C, Axelsson M, V\u00e5gberg M, Sundstr\u00f6m P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis. Neurology. 87:2074\u20132081. https:\/\/doi.org\/10.1212\/WNL.0000000000003331","journal-title":"Neurology."},{"key":"4434_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","volume":"27","author":"E D\u2019Amico","year":"2019","unstructured":"D\u2019Amico E, Zangh\u00ec A, Chisari CG et al (2019) Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience. Mult Scler Relat Disord 27:324\u2013326. https:\/\/doi.org\/10.1016\/j.msard.2018.09.041","journal-title":"Mult Scler Relat Disord"},{"key":"4434_CR7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1352458517713668","volume":"24","author":"T Spelman","year":"2018","unstructured":"Spelman T, Frisell T, Piehl F, Hillert J (2018) Comparative effectiveness of rituximab relative to IFN-\u03b2 or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler J 24:1087\u20131095. https:\/\/doi.org\/10.1177\/1352458517713668","journal-title":"Mult Scler J"},{"key":"4434_CR8","doi-asserted-by":"publisher","first-page":"e0197415","DOI":"10.1371\/journal.pone.0197415","volume":"13","author":"B Scotti","year":"2018","unstructured":"Scotti B, Disanto G, Sacco R, Guigli M\u2019, Zecca C, Gobbi C (2018) Effectiveness and safety of rituximab in multiple sclerosis: an observational study from southern Switzerland. PLoS One 13:e0197415. https:\/\/doi.org\/10.1371\/journal.pone.0197415","journal-title":"PLoS One"},{"key":"4434_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/1352458519858604","volume":"135245851985860","author":"BV Ineichen","year":"2019","unstructured":"Ineichen BV, Moridi T, Granberg T, Piehl F (2019) Rituximab treatment for multiple sclerosis. Mult Scler J 135245851985860:137\u2013152. https:\/\/doi.org\/10.1177\/1352458519858604","journal-title":"Mult Scler J"},{"key":"4434_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"4434_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24:96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Mult Scler"},{"key":"4434_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1444\u20131452. https:\/\/doi.org\/10.1212\/WNL.33.11.1444","journal-title":"Neurology."},{"key":"4434_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M, On Behalf of the Tysabri\u00ae Observational Program (TOP) Investigators (2018) Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler J 24:963\u2013973. https:\/\/doi.org\/10.1177\/1352458517709619","journal-title":"Mult Scler J"},{"key":"4434_CR14","unstructured":"NIH\/NCI (2017) Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. In: Protocol"},{"key":"4434_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdov\u00e1 E (2017) \u201cNo evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23:1179\u20131187. https:\/\/doi.org\/10.1177\/1352458517703193","journal-title":"Mult Scler"},{"key":"4434_CR16","first-page":"06.90","volume":"62","author":"B Cree","year":"2004","unstructured":"Cree B, Lamb S, Chin A, Bonovich D, Islar J, Waubant E, Genain C (2004) Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 62:06.90","journal-title":"Neurology"},{"key":"4434_CR17","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bj\u00f6rck A, Fink K, Islam-Jakobsson P, Malmestr\u00f6m C, Axelsson M, V\u00e5gberg M, Sundstr\u00f6m P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis a retrospective observational study on safety and efficacy. Neurology 87:2074\u20132081","journal-title":"Neurology"},{"key":"4434_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75:320\u2013327. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4011","journal-title":"JAMA Neurol"},{"key":"4434_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/ane.12963","volume":"138","author":"SG Berntsson","year":"2018","unstructured":"Berntsson SG, Kristoffersson A, Bostr\u00f6m I, Feresiadou A, Burman J, Landtblom AM (2018) Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden\u2014outlier or predecessor? Acta Neurol Scand 138:327\u2013331. https:\/\/doi.org\/10.1111\/ane.12963","journal-title":"Acta Neurol Scand"},{"key":"4434_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH (2010) Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67:707\u2013714. https:\/\/doi.org\/10.1001\/archneurol.2010.99","journal-title":"Arch Neurol"},{"key":"4434_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460\u2013471. https:\/\/doi.org\/10.1002\/ana.21867","journal-title":"Ann Neurol"},{"key":"4434_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","volume":"76","author":"Y Naegelin","year":"2019","unstructured":"Naegelin Y, Naegelin P, Von Felten S et al (2019) Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurol 76:274\u2013281. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4239","journal-title":"JAMA Neurol"},{"key":"4434_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9084759","volume":"2018","author":"BI Yamout","year":"2018","unstructured":"Yamout BI, El-Ayoubi NK, Nicolas J et al (2018) Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res 2018:1\u20139. https:\/\/doi.org\/10.1155\/2018\/9084759","journal-title":"J Immunol Res"},{"key":"4434_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","volume":"18","author":"E D\u2019Amico","year":"2019","unstructured":"D\u2019Amico E, Zangh\u00ec A, Gastaldi M et al (2019) Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives. Autoimmun Rev 18:665\u2013672. https:\/\/doi.org\/10.1016\/j.autrev.2019.05.003","journal-title":"Autoimmun Rev"},{"key":"4434_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.25701","volume":"87","author":"P Alping","year":"2020","unstructured":"Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87:688\u2013699. https:\/\/doi.org\/10.1002\/ana.25701","journal-title":"Ann Neurol"},{"key":"4434_CR26","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","volume":"4","author":"P Valentino","year":"2017","unstructured":"Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A (2017) Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study. Neurol Neuroimmunol Neuroinflamm 4:e317. https:\/\/doi.org\/10.1212\/NXI.0000000000000317","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4434_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"4434_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G (2019) Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 15:383\u2013389","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04434-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:03:02Z","timestamp":1659060182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04434-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04434-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"11 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MP Amato received research grants and honoraria as a speaker and member of advisory boards from Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva, Almirall, and Roche. E Portaccio served as scientific advisory board for Biogen Idec and Merck Serono; received honoraria for speaking and funding for traveling from Biogen, Genzyme, Novartis, Merck, and Teva; and received research support from Merck Serono. L. Past\u00f2 and L. Razzolini received editorial grant from Teva, Almirall, Genzyme, and Merck. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the institutional review board of the University of Florence, Italy, and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that neither the article nor portions of it have been previously published elsewhere, that the manuscript is not under consideration for publication in another journal, and will not be submitted elsewhere until the <i>Neurol Sci<\/i> editorial process is completed. All authors consent for the publication of the manuscript in <i>Neurol Sci<\/i>, should the article be accepted by the Editor-in-Chief upon completion of the refereeing process.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}